Oracle Alpha’s Moderna MRNA Stock Holding History

Oracle Alpha’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$350K	Buy	3,282 +193	+6%	+$19.5K	0.63%	49
2023 Q4	$307K	Buy	+3,089	New	+$260K	0.4%	102

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Oracle Alpha's MRNA Position: Q1 2024 in Review

Oracle Alpha increased its Moderna (MRNA) stake by 6.2% in Q1 2024, buying an estimated $19.5K and bringing the position to 3,282 shares worth $350K. The position accounts for 0.63% of the portfolio, ranked #49.

Oracle Alpha first reported a position in MRNA in Q4 2023 and has held it in 2 quarters since. 903 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

Oracle Alpha held 3,282 shares of Moderna worth $350K as of Q1 2024.
Oracle Alpha bought 193 Moderna shares in Q1 2024, an estimated $19.5K.
Moderna made up 0.63% of Oracle Alpha's portfolio in Q1 2024, its #49 holding.
Oracle Alpha first reported a position in Moderna in Q4 2023 and has held it in 2 quarters since.
903 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.